At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HCC Warrior Met Coal LLC
Not Yet Opened 10-09 16:00:00 EDT
93.07
+3.27
+3.64%
盘后93.07
+0.000.00%
19:30 EDT
High94.93Low89.83Vol565.01K
Open90.27D1 Closing89.80Amplitude5.68%
Mkt Cap4.89BTradable Cap4.82BTotal Shares52.57M
T/O52.64MT/O Rate1.09%Tradable Shares51.78M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer
GlobeNewswire  ·  09:47
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer
RBC Capital Keeps Their Hold Rating on Warrior Met Coal (HCC)
TIPRANKS  ·  10-09
RBC Capital Keeps Their Hold Rating on Warrior Met Coal (HCC)
Warrior Met Coal is Maintained at Buy by UBS
Dow Jones  ·  10-09
Warrior Met Coal is Maintained at Buy by UBS
UBS Adjusts Price Target on Warrior Met Coal to $102 From $98, Maintains Buy Rating
MT Newswires Live  ·  10-08
UBS Adjusts Price Target on Warrior Met Coal to $102 From $98, Maintains Buy Rating
Warrior Met Coal price target raised to $102 from $98 at UBS
TIPRANKS  ·  10-08
Warrior Met Coal price target raised to $102 from $98 at UBS
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
GlobeNewswire  ·  10-06
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
GlobeNewswire  ·  09-28
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
Warrior Met Coal (HCC) Tests Investor Patience As Blue Creek Fuels Undervalued View
Simply Wall St.  ·  09-25
Warrior Met Coal (HCC) Tests Investor Patience As Blue Creek Fuels Undervalued View
NYSE Order Imbalance 56938.0 Shares on Sell Side
THOMSON REUTERS  ·  09-17
NYSE Order Imbalance 56938.0 Shares on Sell Side
RBC Raises Price Target on Warrior Met Coal to $110 From $90, Keeps Sector Perform Rating
MT Newswires Live  ·  09-16
RBC Raises Price Target on Warrior Met Coal to $110 From $90, Keeps Sector Perform Rating
WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC
GlobeNewswire  ·  09-14
WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
GlobeNewswire  ·  09-09
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
Press Release: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Dow Jones  ·  09-08
Press Release: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
GlobeNewswire  ·  09-02
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
GlobeNewswire  ·  09-02
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire  ·  09-01
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Tokio Marine HCC International Acquires UK-Based Direct Commercial
MT Newswires Live  ·  08-31
Tokio Marine HCC International Acquires UK-Based Direct Commercial
Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
Dow Jones  ·  08-28
Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
IMMUNEONCO-B Advances Phase II Trial for First-Line Advanced Liver Cancer Therapy With Initial Patient Dosing Completed
Stock News  ·  08-27
IMMUNEONCO-B Advances Phase II Trial for First-Line Advanced Liver Cancer Therapy With Initial Patient Dosing Completed
Warrior Met Coal CEO Walter J. Scheller Sells 50,000 Shares for $5.5 Million
Reuters  ·  08-26
Warrior Met Coal CEO Walter J. Scheller Sells 50,000 Shares for $5.5 Million

Introduction

Company Name.
Warrior Met Coal LLC
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Warrior Met Coal, Inc. produces and exports non-thermal metallurgical coal for the steel industry. It operates two underground mines located in Alabama. The company sells its metallurgical coal to a customer base of blast furnace steel producers located primarily in Europe, South America, and Asia. It also sells natural gas, which is extracted as a byproduct from coal production. Warrior Met Coal, Inc. was incorporated in 2015 and is headquartered in Brookwood, Alabama.
Issue price:
--